| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |


From the Cancer Research Campaign Department of Medical
Oncology,*
Cancer Research Campaign Beatson Laboratories,
Glasgow University, Glasgow; the Department of
Pathology,
Stobhill National Health
Service Trust, Glasgow; Haematology
Research,
Pembury Hospital, Tunbridge Wells,
Kent; and the Beatson Oncology Centre,§
Western
Infirmary, Glasgow, United Kingdom
Mounting evidence suggests that aberrant methylation of CpG islands is a major pathway leading to the inactivation of tumor suppressor genes and the development of cancer. Recent studies on colorectal and gastric cancer have defined a CpG island methylator phenotype (CIMP), which involves the targeting of multiple genes by promoter hypermethylation. To determine the role of methylation in ovarian cancer, we have investigated the methylation status of 93 primary ovarian tumors at ten loci using methylation-specific polymerase chain reaction (MSP). Seven of the loci (BRCA1, HIC1, MINT25, MINT31, MLH1, p73 and hTR) were found to be methylated in a significant proportion of the ovarian tumors, and methylation of at least one of these was found in the majority (71%) of samples. Although concurrent methylation of multiple genes was commonly seen, this did not seem to be due to a single CIMP phenotype. Instead the results suggest the presence of at least three groups of tumors, two CIMP-positive groups, each susceptible to methylation of a different subset of genes, and a further group of tumors not susceptible to CpG island methylation, at least at the loci studied.
This article has been cited by other articles:
![]() |
C. J. Marsit, E. A. Houseman, B. C. Christensen, K. Eddy, R. Bueno, D. J. Sugarbaker, H. H. Nelson, M. R. Karagas, and K. T. Kelsey Examination of a CpG Island Methylator Phenotype and Implications of Methylation Profiles in Solid Tumors Cancer Res., November 1, 2006; 66(21): 10621 - 10629. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W.Y. Chan, S. H. Wei, P. Wen, Z. Wang, D. E. Matei, J. C. Liu, S. Liyanarachchi, R. Brown, K. P. Nephew, P. S. Yan, et al. Hypermethylation of 18S and 28S Ribosomal DNAs Predicts Progression-Free Survival in Patients with Ovarian Cancer Clin. Cancer Res., October 15, 2005; 11(20): 7376 - 7383. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Teodoridis, J. Hall, S. Marsh, H. D. Kannall, C. Smyth, J. Curto, N. Siddiqui, H. Gabra, H. L. McLeod, G. Strathdee, et al. CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian Cancer Cancer Res., October 1, 2005; 65(19): 8961 - 8967. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. B. Makarla, M. H. Saboorian, R. Ashfaq, K. O. Toyooka, S. Toyooka, J. D. Minna, A. F. Gazdar, and J. O. Schorge Promoter Hypermethylation Profile of Ovarian Epithelial Neoplasms Clin. Cancer Res., August 1, 2005; 11(15): 5365 - 5369. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Liu, L.-E Wang, L. Wang, K. H. Lu, G. B. Mills, M. L. Bondy, and Q. Wei Methylation and Messenger RNA Expression of p15INK4b but Not p16INK4a Are Independent Risk Factors for Ovarian Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4968 - 4976. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.-H. Shen, K. Y.-K. Chan, U.-S. Khoo, H. Y.-S. Ngan, W.-C. Xue, P.-M. Chiu, P. Ip, and A. N.-Y. Cheung Epigenetic and genetic alterations of p33ING1b in ovarian cancer Carcinogenesis, April 1, 2005; 26(4): 855 - 863. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. I. de Caceres, C. Battagli, M. Esteller, J. G. Herman, E. Dulaimi, M. I. Edelson, C. Bergman, H. Ehya, B. L. Eisenberg, and P. Cairns Tumor Cell-Specific BRCA1 and RASSF1A Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients Cancer Res., September 15, 2004; 64(18): 6476 - 6481. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Parrella, M. L. Poeta, A. P. Gallo, M. Prencipe, M. Scintu, A. Apicella, R. Rossiello, G. Liguoro, D. Seripa, C. Gravina, et al. Nonrandom Distribution of Aberrant Promoter Methylation of Cancer-Related Genes in Sporadic Breast Tumors Clin. Cancer Res., August 15, 2004; 10(16): 5349 - 5354. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Widschwendter, G. Jiang, C. Woods, H. M. Muller, H. Fiegl, G. Goebel, C. Marth, E. Muller-Holzner, A. G. Zeimet, P. W. Laird, et al. DNA Hypomethylation and Ovarian Cancer Biology Cancer Res., July 1, 2004; 64(13): 4472 - 4480. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Gifford, J. Paul, P. A. Vasey, S. B. Kaye, and R. Brown The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients Clin. Cancer Res., July 1, 2004; 10(13): 4420 - 4426. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Strathdee, B.R. Davies, J.K. Vass, N. Siddiqui, and R. Brown Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene Carcinogenesis, May 1, 2004; 25(5): 693 - 701. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Terasawa, S. Sagae, M. Toyota, K. Tsukada, K. Ogi, A. Satoh, H. Mita, K. Imai, T. Tokino, and R. Kudo Epigenetic Inactivation of TMS1/ASC in Ovarian Cancer Clin. Cancer Res., March 15, 2004; 10(6): 2000 - 2006. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rathi, A. K. Virmani, K. Harada, C. F. Timmons, K. Miyajima, R. J. Hay, D. Mastrangelo, A. Maitra, G. E. Tomlinson, and A. F. Gazdar Aberrant Methylation of the HIC1 Promoter Is a Frequent Event in Specific Pediatric Neoplasms Clin. Cancer Res., September 1, 2003; 9(10): 3674 - 3678. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-P. J. Issa Methylation and Prognosis: Of Molecular Clocks and Hypermethylator Phenotypes Clin. Cancer Res., August 1, 2003; 9(8): 2879 - 2881. [Full Text] [PDF] |
||||
![]() |
C.-M. Chen, H.-L. Chen, T. H.-C. Hsiau, A. H.-A. Hsiau, H. Shi, G. J. R. Brock, S. H. Wei, C. W. Caldwell, P. S. Yan, and T. H.-M. Huang Methylation Target Array for Rapid Analysis of CpG Island Hypermethylation in Multiple Tissue Genomes Am. J. Pathol., July 1, 2003; 163(1): 37 - 45. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Fu, E. J. Campbell, T. G. Shepherd, and M. W. Nachtigal Epigenetic Regulation of Proprotein Convertase PACE4 Gene Expression in Human Ovarian Cancer Cells Mol. Cancer Res., June 1, 2003; 1(8): 569 - 576. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. P. Whitcomb, D. G. Mutch, T. J. Herzog, J. S. Rader, R. K. Gibb, and P. J. Goodfellow Frequent HOXA11 and THBS2 Promoter Methylation, and a Methylator Phenotype in Endometrial Adenocarcinoma Clin. Cancer Res., June 1, 2003; 9(6): 2277 - 2287. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y Kaneko, S Sakurai, M Hironaka, S Sato, S Oguni, Y Sakuma, K Sato, K Sugano, and K Saito Distinct methylated profiles in Helicobacter pylori dependent and independent gastric MALT lymphomas Gut, May 1, 2003; 52(5): 641 - 646. [Abstract] [Full Text] |
||||
![]() |
A. Rathi, A. K. Virmani, J. O. Schorge, K. J. Elias, R. Maruyama, J. D. Minna, S. C. Mok, L. Girard, D. A. Fishman, and A. F. Gazdar Methylation Profiles of Sporadic Ovarian Tumors and nonmalignant Ovaries from High-Risk Women Clin. Cancer Res., November 1, 2002; 8(11): 3324 - 3331. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-P. Issa Epigenetic Variation and Human Disease J. Nutr., August 1, 2002; 132(8): 2388S - 2392. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Jazaeri, C. J. Yee, C. Sotiriou, K. R. Brantley, J. Boyd, and E. T. Liu Gene Expression Profiles of BRCA1-Linked, BRCA2-Linked, and Sporadic Ovarian Cancers J Natl Cancer Inst, July 3, 2002; 94(13): 990 - 1000. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Wei, C.-M. Chen, G. Strathdee, J. Harnsomburana, C.-R. Shyu, F. Rahmatpanah, H. Shi, S.-W. Ng, P. S. Yan, K. P. Nephew, et al. Methylation Microarray Analysis of Late-Stage Ovarian Carcinomas Distinguishes Progression-free Survival in Patients and Identifies Candidate Epigenetic Markers Clin. Cancer Res., July 1, 2002; 8(7): 2246 - 2252. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Shen, N. Ahuja, Y. Shen, N. A. Habib, M. Toyota, A. Rashid, and J.-P. J. Issa DNA Methylation and Environmental Exposures in Human Hepatocellular Carcinoma J Natl Cancer Inst, May 15, 2002; 94(10): 755 - 761. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Raymond, S. Faivre, S. Chaney, J. Woynarowski, and E. Cvitkovic Cellular and Molecular Pharmacology of Oxaliplatin Mol. Cancer Ther., January 1, 2002; 1(3): 227 - 235. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |